Nachrichten zur Eli Lilly & Co. Aktie

Futures Dip; Palantir Soars On Surging AI Demand

Other key earnings movers include Eli Lilly, Spotify and Vertex Pharmaceuticals.…

Dank Abnehmmittel: Pharmakonzern Eli Lilly sieht weiteren Umsatzsprung

INDIANAPOLIS (dpa-AFX) - Nach dem Verkaufsstart seines Abnehmmittels traut sich der Pharmakonzern Eli Lilly 2024…

Zepbound Maker Eli Lilly Forecasts Strong Profits Amid Rollout Of Weight Loss Drug

Zepbound, which contains the active ingredient tirzepatide, is expected to become one of the best selling drugs of all time.…

Eli Lilly Veers Higher On Fourth-Quarter Beat

Eli Lilly Scored a strong Q4 win and provided healthy guidance Tuesday. Shares moved toward a profit-taking zone following a…

Eli Lilly leaps as weight-loss-drug sales drive earnings and 2024 outlook

Eli Lillys market value is more than $100 million north of Teslas.…

Eli Lilly rallies toward a fifth straight record close after earnings beat

…

Dow seen slightly lower but Eli Lilly jumps on earnings beat

7:00am: Modest falls expected; Eli Lilly jumps on earnings beat Stock futures in New York edged lower on Tuesday as…

Dow opens higher while Eli Lilly climbs on earnings beat

9:45am: Stocks start Tuesday on the front foot Stocks made steady progress when trading began on Tuesday boosted by gains…

Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlook

…

These Stocks Are Moving the Most Today: Palantir, Eli Lilly, Spotify, BP, FMC, Coherent, Chegg, and More

…

Eli Lilly beats profit forecast amid soaring weight-loss drug demand By Investing.com

Eli Lilly beats profit forecast amid soaring weight-loss drug demand…

Eli Lilly results blow past estimates on strong Zepbound launch, higher Mounjaro prices

The quarterly results are the first to include sales of Eli Lillys new weight loss drug Zepbound, which won FDA…

Eli Lilly earnings beat by $0.18, revenue topped estimates By Investing.com

Eli Lilly earnings beat by $0.18, revenue topped estimates…

Eli Lilly earnings ahead, Toyota lifts annual guidance - whats moving markets By Investing.com

Eli Lilly earnings ahead, Toyota lifts annual guidance - whats moving markets…

Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales

Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.…

Eli Lilly’s Obesity Drug Will Be the Focus of Earnings

…

Third Bridges Brown on Eli Lillys 4Q Report

Third Bridge, Global Sector Lead: Health Care, Lee Brown to discuss the big movers on the back of analyst recommendations…

Is It Too Late to Buy Eli Lilly Stock? @themotleyfool #stocks $LLY

Growth may slow, and its valuation is looking precarious.…

Is It Too Late to Buy Eli Lilly Stock?

Growth may slow, and its valuation is looking precarious.…

The Zacks Analyst Blog Highlights Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas

Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas are included in this Analyst Blog.…

After a 90% Gain, Is It Too Late to Buy Eli Lilly?

…

After a 90% Gain, Is It Too Late to Buy Eli Lilly?

Its drug tirzepatide showed top efficacy as a weight-loss treatment according to the latest real-world data.…

After a 90% Gain, Is It Too Late to Buy Eli Lilly? @themotleyfool #stocks $LLY $NVO

Its drug tirzepatide showed top efficacy as a weight-loss treatment according to the latest real-world data.…

4 Large Drug Stocks Trying to Survive the Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk…

Top Stock Reports for Eli Lilly, Danaher & Citigroup

Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR)…

Want to cash in on the weight-loss drug boom? Morgan Stanley names 4 global stocks

The positive response to anti-obesity drugs has put Eli Lilly and Novo Nordisk in the spotlight.…

Why Eli Lilly Stock Topped the Market Today

One of its more recently approved drugs will be launched into a white-hot market.…

Eli Lilly (LLY) to Report Q4 Earnings: Whats in the Cards?

On Eli Lillys (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide…

Biogen, Eisai, And Eli Lilly: The Potential Pitfalls Of Anti-Amyloid Antibody Drugs

…

Could Eli Lilly Be a Trillion-Dollar Company by 2030?

Eli Lilly is the worlds largest healthcare company by market cap, and the 10th most valuable business in the world.…

How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug

Eli Lilly has a dual-track approach to make more of its fast-growing diabetes and obesity drugs.…

Eli Lillys Wegovy rival Mounjaro gets UK green light

Mounjaro, Eli Lillys (NYSE:LLY) rival weightloss drug to Wegovy and Ozempic, is to be made available in the UK after receiving…

Pharma’s Weight-Loss Bonanza

The success of Ozempic and Wegovy has turned Novo Nordisk into Europe’s biggest company. But Eli Lilly’s newest version of…

Eli Lilly gene therapy restores hearing in Phase 1/2 trial

…

Stock Of The Day Lilly Is In A Buy Zone. And Its Not Tied To Obesity.

An Eli Lilly subsidiary thinks it might have the solution to a genetic form of hearing loss.…

Eli Lillys Zepbound is off to a strong start, but heres what needs to happen to push shares higher

Investors will be tuning into the companys fourth quarter earnings call on Feb. 6, eager to hear more about how…

Eli Lilly gene therapy allows child born deaf to hear, clinical trial shows

…

Cramer taps Eli Lilly as a new member of the Magnificent Seven if Tesla earnings falter

CNBCs Jim Cramer said Tesla may have hit a "growth pause," compared to its Big Tech peers that are still…

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class,…

dpa-AFX ProFeed